Cargando…

Pharmacologic effects of oseltamivir in immunocompromised adult patients as assessed by population PK/PD analysis and drug‐disease modelling for dosing regimen optimization

AIM: Pharmacologic effects were analysed to determine a dose recommendation for oseltamivir in immunocompromised (IC) adults with influenza. METHODS: Quantitative clinical pharmacology methods were applied to data from 160 adult IC patients (aged 18‐78 years) from two studies (NV20234, 150 patients;...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sturm, Stefan, Lemenuel‐Diot, Annabelle, Patel, Kashyap, Gibiansky, Leonid, Bhardwaj, Rajinder, Smith, Patrick F., Dang, Steve, Zwanziger, Elke, Nasmyth‐Miller, Clare, Ravva, Patanjali
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246794/ https://www.ncbi.nlm.nih.gov/pubmed/32808306 http://dx.doi.org/10.1111/bcp.14523

Ejemplares similares

Mechanistic Population Pharmacokinetic Model of Oseltamivir and Oseltamivir Carboxylate Accounting for Physiological Changes to Predict Exposures in Neonates and Infants
por: Gibiansky, Leonid, et al.
Publicado: (2020)

Pharmacokinetics and Pharmacodynamics of Conventional-Dose vs Triple-Dose Oseltamivir in Severely Immunocompromised Children With Influenza
por: Bautista, Francisco, et al.
Publicado: (2019)

Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection
por: Boianelli, Alessandro, et al.
Publicado: (2016)

Safety, Resistance, and Efficacy Results from a Phase IIIb Study of Conventional- and Double-Dose Oseltamivir Regimens for Treatment of Influenza in Immunocompromised Patients
por: Mitha, Essack, et al.
Publicado: (2019)

Progressive emergence of an oseltamivir‐resistant A(H3N2) virus over two courses of oseltamivir treatment in an immunocompromised paediatric patient
por: Hurt, Aeron C., et al.
Publicado: (2013)

Oseltamivir‐resistant influenza A 2009 H1N1 virus in immunocompromised patients
por: Couturier, Brianne A., et al.
Publicado: (2010)

How Semiphysiological Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports Phase II Dose Selection of RO7049389, A Novel Anti–Hepatitis B Virus Drug
por: Cosson, Valérie, et al.
Publicado: (2021)

PK-PD Modeling and Optimal Dosing Regimen of Acetylkitasamycin against Streptococcus suis in Piglets
por: Huang, Anxiong, et al.
Publicado: (2022)

Machine learning for decision makers: cognitive computing fundamentals for better decision making
por: Kashyap, Patanjali
Publicado: (2017)

Optimal regimens based on PK/PD cutoff evaluation of ceftiofur against Actinobacillus pleuropneumoniae in swine
por: Sun, Da, et al.
Publicado: (2020)

Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study
por: Huang, Anxiong, et al.
Publicado: (2022)

The role of population PK–PD modelling in paediatric clinical research
por: De Cock, Roosmarijn F. W., et al.
Publicado: (2010)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers
por: Jang, Kyungho, et al.
Publicado: (2017)

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study
por: Shokri, Fazlollah, et al.
Publicado: (2023)

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study
por: Shokri, Fazlollah, et al.
Publicado: (2023)

Population pharmacokinetics of oseltamivir and oseltamivir carboxylate in obese and non‐obese volunteers
por: Chairat, Kalayanee, et al.
Publicado: (2016)

Treatment of Immunocompromised, Critically Ill Patients with Influenza A H1N1 Infection with a Combination of Oseltamivir, Amantadine, and Zanamivir
por: Meijer, Wouter J., et al.
Publicado: (2015)

PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma
por: Koiwai, Kimiko, et al.
Publicado: (2021)

Malaria PK/PD and the Role Pharmacometrics Can Play in the Global Health Arena: Malaria Treatment Regimens for Vulnerable Populations
por: Hughes, Emma, et al.
Publicado: (2021)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

In vitro dynamic pharmacokinetic/pharmacodynamic(PK/PD) modeling and PK/PD cutoff of cefquinome against Haemophilus parasuis
por: Xiao, Xia, et al.
Publicado: (2015)

Oseltamivir dosing with haemofiltration
por: Tomlin, M, et al.
Publicado: (2010)

Use of a Population Pharmacokinetic Approach for the Clinical Development of a Fixed-Dose Subcutaneous Formulation of Trastuzumab
por: Hourcade-Potelleret, F, et al.
Publicado: (2014)

Chemical Analysis and Transplacental Transfer of Oseltamivir and Oseltamivir Carboxylic Acid in Pregnant Rats
por: Lin, Chia-Chun, et al.
Publicado: (2012)

Intrahost emergent dynamics of oseltamivir-resistant virus of pandemic influenza A (H1N1) 2009 in a fatally immunocompromised patient
por: Hamada, Nobuyuki, et al.
Publicado: (2012)

SwissPK(cdw) – A clinical data warehouse for the optimization of pediatric dosing regimens
por: Goers, Roland, et al.
Publicado: (2021)

In vivo Pharmacokinetic and Pharmacodynamic (PK/PD) Modeling and Establishment of the PK/PD Cutoff of Florfenicol Against Pasteurella multocida in Ducks
por: Xiao, Xia, et al.
Publicado: (2021)

Decreased Hospital Length of Stay With Early Administration of Oseltamivir in Patients Hospitalized With Influenza
por: Dou, Lin, et al.
Publicado: (2020)

Epidemiological and PK/PD cutoff values determination and PK/PD-based dose assessment of gamithromycin against Haemophilus parasuis in piglets
por: Zhou, Yu-Feng, et al.
Publicado: (2020)

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Population pharmacokinetic and exposure–response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
por: Gibiansky, Ekaterina, et al.
Publicado: (2021)

Assay to Detect Oseltamivir Resistance
por: Suwannakarn, Kamol, et al.
Publicado: (2006)

Rapid Emergence of Oseltamivir Resistance
por: Sy, Cheng Len, et al.
Publicado: (2010)

Oseltamivir in pregnancy and birth outcomes
por: Ehrenstein, Vera, et al.
Publicado: (2018)

Promising New Salt of Oseltamivir
por: Kalashnikov, A. I., et al.
Publicado: (2021)

New Data for Nebivolol after In Silico PK Study: Focus on Young Patients and Dosage Regimen
por: Marques, Lara, et al.
Publicado: (2022)

Plasma Concentrations of Oseltamivir and Oseltamivir Carboxylate in Critically Ill Children on Extracorporeal Membrane Oxygenation Support
por: Wildschut, Enno D., et al.
Publicado: (2010)

PK/PD analysis of trazodone and gabapentin in neuropathic pain rodent models: Translational PK‐PD modeling from nonclinical to clinical development
por: Oggianu, Laura, et al.
Publicado: (2023)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d2vko81mbum7cf71nqnjrud5hs